Congress Questions Cigna's Large-Scale Denial of Insurance Claims

ProPublica reported that the House Energy and Commerce Committee formally requested corporate documents from Cigna to examine the company's practice of denying claims using the PxDx system without opening patient files. This congressional investigation marks a significant escalation from media reporting to governmental oversight — and it carries implications for how payers process claims that should matter to every physician practice in the country.

When Congress investigates a payer's denial practices, it signals that the problem has moved beyond an industry dispute between providers and insurers into a matter of public interest and consumer protection.

What Congress Is Investigating

The investigation centers on Cigna's PxDx system, which was first exposed by ProPublica's reporting in March 2023. The key findings that prompted congressional attention include:

• Cigna denied over 300,000 claims in a two-month period using the PxDx algorithm
• Medical directors reviewing flagged claims spent an average of 1.2 seconds per case
• Claims were denied based on diagnosis-procedure code combinations without review of individual patient medical records
• The system effectively allowed medical directors to batch-approve denials without clinical evaluation

The congressional request for corporate documents suggests that lawmakers are looking for internal evidence of how the system was designed, how it was used, and whether Cigna's leadership was aware that claims were being denied without meaningful medical review.

Why Congressional Attention Matters

Congressional investigations can lead to legislative action. The House Energy and Commerce Committee has jurisdiction over health insurance regulation, and its investigations have historically preceded significant healthcare legislation. While there is no guarantee that this investigation will produce new laws, it creates political pressure on payers that can influence behavior even without legislation.

For physician practices, the investigation matters for several reasons:

First, it validates what practices have long experienced — that some denials are not the product of clinical judgment but of automated systems designed to reduce claim payments. This validation has both practical and psychological value. It is easier to justify the resources required for a robust denial management program when the problem is acknowledged by federal oversight bodies, not just by frustrated billing staff.

Second, the investigation creates a public record. Congressional hearings, document requests, and committee reports produce evidence that can be used in regulatory complaints, legal proceedings, and payer contract negotiations. When a practice can point to a congressional investigation that documented systematic denial practices, it strengthens the case for contract provisions that protect against automated denials.

The Regulatory Ripple Effect

Congressional attention typically triggers parallel scrutiny from regulatory agencies. CMS, state insurance regulators, and the HHS Office of Inspector General have all shown increasing interest in payer denial practices. The timing aligns with CMS's Interoperability and Prior Authorization Rule, which includes provisions requiring payers to provide specific reasons for denials — a requirement that is difficult to satisfy when denials are generated algorithmically without individual review.

State regulators are also watching. Several states have introduced or passed legislation specifically addressing the use of AI and algorithms in insurance coverage decisions. Congressional attention to the issue raises its profile and may accelerate state-level action.

What Practices Should Do

Congressional investigations unfold over months or years. In the meantime, physician practices need to continue managing denials through their existing processes. However, the investigation provides strategic context that can inform those processes:

When appealing Cigna denials that appear to have been generated without individual clinical review, practices should note that in their appeal documentation. Stating that the denial does not appear to reflect review of the patient's specific clinical circumstances, and requesting individualized clinical review, establishes a record that has value beyond the individual appeal.

Practices should also consider filing complaints with their state insurance regulator when they identify patterns of denials that suggest algorithmic rather than clinical review. Regulatory complaints contribute to the broader evidence base that supports enforcement action and legislative reform.

The congressional investigation is a positive development for physician practices. It is not, however, a substitute for the daily work of documenting clinical care thoroughly, submitting complete claims, and appealing denials with patient-specific evidence. That work remains the most reliable path to revenue recovery regardless of the political and regulatory environment.